89,234 Shares in Celcuity, Inc. $CELC Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new position in shares of Celcuity, Inc. (NASDAQ:CELC) during the second quarter, HoldingsChannel.com reports. The firm bought 89,234 shares of the company’s stock, valued at approximately $9,336,000.

Several other large investors have also added to or reduced their stakes in CELC. Avoro Capital Advisors LLC bought a new position in shares of Celcuity in the fourth quarter worth approximately $310,302,000. Bank of America Corp DE bought a new stake in shares of Celcuity during the 2nd quarter valued at $153,928,000. NEA Management Company LLC lifted its stake in shares of Celcuity by 64.9% during the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after buying an additional 1,391,300 shares in the last quarter. State Street Corp lifted its stake in shares of Celcuity by 126.6% during the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after buying an additional 914,887 shares in the last quarter. Finally, UBS Group AG lifted its stake in shares of Celcuity by 910.1% during the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after buying an additional 769,891 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Analysts Set New Price Targets

CELC has been the subject of a number of analyst reports. Craig Hallum reiterated a “buy” rating and issued a $178.00 price target on shares of Celcuity in a research note on Wednesday, July 15th. HC Wainwright reaffirmed a “buy” rating and issued a $155.00 price objective on shares of Celcuity in a research note on Friday, August 14th. Wall Street Zen downgraded Celcuity from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Citigroup reissued a “market outperform” rating on shares of Celcuity in a report on Monday, August 17th. Finally, Citizens Jmp restated a “market outperform” rating and issued a $177.00 price target on shares of Celcuity in a research note on Monday, August 17th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $154.55.

Celcuity Trading Down 1.9%

CELC opened at $93.24 on Friday. The stock has a 50-day moving average of $94.63 and a 200 day moving average of $107.28. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. Celcuity, Inc. has a 12 month low of $44.42 and a 12 month high of $151.02. The firm has a market cap of $4.56 billion, a P/E ratio of -21.68 and a beta of 0.20.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). As a group, research analysts forecast that Celcuity, Inc. will post -4.75 EPS for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.